M. D. I. Uddin

Array ( [id] => 11829930 [patent_doc_number] => 09726666 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-08 [patent_title] => 'Diagnosing and treating inflammatory diseases' [patent_app_type] => utility [patent_app_number] => 14/105628 [patent_app_country] => US [patent_app_date] => 2013-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 139 [patent_figures_cnt] => 272 [patent_no_of_words] => 309181 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14105628 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10953304 [patent_doc_number] => 20140356326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-04 [patent_title] => 'BIOLOGICALLY ACTIVE PROTEINS HAVING INCREASED IN VIVO AND/OR IN VITRO STABILITY' [patent_app_type] => utility [patent_app_number] => 14/102297 [patent_app_country] => US [patent_app_date] => 2013-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 47 [patent_no_of_words] => 48572 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14102297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10422551 [patent_doc_number] => 20150307562 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'ENGINEERED SECRETED PROTEINS AND METHODS' [patent_app_type] => utility [patent_app_number] => 14/443773 [patent_app_country] => US [patent_app_date] => 2013-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 42 [patent_figures_cnt] => 42 [patent_no_of_words] => 70841 [patent_no_of_claims] => 140 [patent_no_of_ind_claims] => 15 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14443773 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11487100 [patent_doc_number] => 09593165 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-03-14 [patent_title] => 'Antibody capable of specifically recognizing transferrin receptor' [patent_app_type] => utility [patent_app_number] => 14/441307 [patent_app_country] => US [patent_app_date] => 2013-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 11 [patent_no_of_words] => 18944 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 2242 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14441307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12326163 [patent_doc_number] => 09944706 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-17 [patent_title] => Immunoproteases [patent_app_type] => utility [patent_app_number] => 14/440947 [patent_app_country] => US [patent_app_date] => 2013-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 10799 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14440947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10428990 [patent_doc_number] => 20150314001 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'LIQUID FORMULATION COMPRISING GM-CSF NEUTRALIZING COMPOUND' [patent_app_type] => utility [patent_app_number] => 14/429204 [patent_app_country] => US [patent_app_date] => 2013-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 34997 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14429204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10457872 [patent_doc_number] => 20150342888 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-03 [patent_title] => 'LYOPHILIZED FORMULATION COMPRISING GM-CSF NEUTRALIZING COMPOUND' [patent_app_type] => utility [patent_app_number] => 14/428489 [patent_app_country] => US [patent_app_date] => 2013-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28484 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14428489 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330104 [patent_doc_number] => 20140056886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'Humanized Anti-IL-20 Antibody And Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/066018 [patent_app_country] => US [patent_app_date] => 2013-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 7835 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14066018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9597676 [patent_doc_number] => 20140194358 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-10 [patent_title] => 'PROMININ-1 PEPTIDE FRAGMENTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/064502 [patent_app_country] => US [patent_app_date] => 2013-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 36853 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14064502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11722391 [patent_doc_number] => 09695239 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-07-04 [patent_title] => 'Microtubule-modifying compound' [patent_app_type] => utility [patent_app_number] => 14/436568 [patent_app_country] => US [patent_app_date] => 2013-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 60 [patent_figures_cnt] => 40 [patent_no_of_words] => 49492 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14436568 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10428985 [patent_doc_number] => 20150313996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-05 [patent_title] => 'COMPOSITION FOR STABILIZING FUSION PROTEIN IN WHICH PROTEIN AND FC DOMAIN ARE FUSED' [patent_app_type] => utility [patent_app_number] => 14/439644 [patent_app_country] => US [patent_app_date] => 2013-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 5818 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14439644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10381961 [patent_doc_number] => 20150266968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-24 [patent_title] => 'POLYPEPTIDES CAPABLE OF CELLULAR INTERNALIZATION' [patent_app_type] => utility [patent_app_number] => 14/437063 [patent_app_country] => US [patent_app_date] => 2013-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 36471 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14437063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10398197 [patent_doc_number] => 20150283205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-08 [patent_title] => 'THY1 (CD90) AS A NOVEL THERAPY TO CONTROL ADIPOSE TISSUE ACCUMULATION' [patent_app_type] => utility [patent_app_number] => 14/437378 [patent_app_country] => US [patent_app_date] => 2013-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 24105 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14437378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10340475 [patent_doc_number] => 20150225480 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-13 [patent_title] => 'HUMAN ALPHA-FOLATE RECEPTOR CHIMERIC ANTIGEN RECEPTOR' [patent_app_type] => utility [patent_app_number] => 14/432664 [patent_app_country] => US [patent_app_date] => 2013-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 27154 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14432664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10127659 [patent_doc_number] => RE045763 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2015-10-20 [patent_title] => 'Antibodies to troponin I and methods of use thereof' [patent_app_type] => reissue [patent_app_number] => 14/035420 [patent_app_country] => US [patent_app_date] => 2013-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 17 [patent_no_of_words] => 22462 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14035420 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9362688 [patent_doc_number] => 20140072561 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-03-13 [patent_title] => 'FACTOR VIII, VON WILLEBRAND FACTOR OR COMPLEXES THEREOF WITH PROLONGED IN VIVO HALF-LIFE' [patent_app_type] => utility [patent_app_number] => 14/028869 [patent_app_country] => US [patent_app_date] => 2013-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 17136 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14028869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10346233 [patent_doc_number] => 20150231239 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-08-20 [patent_title] => 'COMPOSITIONS AND METHODS FOR RENDERING TUMOR CELLS SUSCEPTIBLE TO CD8+ T CELL-MEDIATED KILLING' [patent_app_type] => utility [patent_app_number] => 14/427847 [patent_app_country] => US [patent_app_date] => 2013-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 10098 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14427847 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11263285 [patent_doc_number] => 09487571 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-08 [patent_title] => 'Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity' [patent_app_type] => utility [patent_app_number] => 14/026671 [patent_app_country] => US [patent_app_date] => 2013-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 43 [patent_no_of_words] => 72941 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14026671 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9204925 [patent_doc_number] => 20140004102 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-01-02 [patent_title] => 'Methods for treating and/or limiting development of diabetes' [patent_app_type] => utility [patent_app_number] => 14/026145 [patent_app_country] => US [patent_app_date] => 2013-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 13954 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14026145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11814945 [patent_doc_number] => 09718887 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-08-01 [patent_title] => 'Methods and products for preventing and/or treating metastatic cancer' [patent_app_type] => utility [patent_app_number] => 14/426534 [patent_app_country] => US [patent_app_date] => 2013-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 19943 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14426534 [rel_patent_id] =>[rel_patent_doc_number] =>)